EPISODE · Mar 19, 2026 · 11 MIN
From London: With science from the Francis Crick Institute, ALTx Therapeutics launched with £12.55m last month to target cancers that rely on the Alternative Lengthening of Telomeres (ALT)
from BiotechTV - News · host BiotechTV
From Syncona's Capital Markets Day, ALTx founder and Francis Crick researcher Simon Boulton describes ALTs and the science behind how the company plans to target them.
Embed this episode
Ready to play
From London: With science from the Francis Crick Institute, ALTx Therapeutics launched with £12.55m last month to target cancers that rely on the Alternative Lengthening of Telomeres (ALT)
0:00
11:34
1×
No transcript for this episode yet
Similar Episodes
No similar episodes found.
Similar Podcasts
No similar podcasts found.
Frequently Asked Questions
How long is this episode of BiotechTV - News?
This episode is 11 minutes long.
When was this BiotechTV - News episode published?
This episode was published on March 19, 2026.
Can I download this BiotechTV - News episode?
Yes. Use the download control on the episode player to save the publisher-provided media file.
URL copied to clipboard!